Navigation Links
Healthcare Technologies Reports 2007 Nine Months & Third Quarter Results
Date:11/23/2007

PETACH TIKVA, Israel, November 23 /PRNewswire-FirstCall/ -- Healthcare Technologies, Ltd. (NASDAQ: HCTL), today announced unaudited results for nine months and the third quarter ended September 30, 2007.

Revenues for the third quarter of 2007 were $4.0 million, as compared to $3.1 million for the corresponding quarter last year. The third quarter gross profit was $1.4 million, as compared to $1.0 million in the third quarter of 2006. The net profit for the quarter was $189 thousand or $0.02 per share, compared to $34 thousand, or $0 per share for the third quarter of last year.

Revenues for the first nine months of 2007 were $11.7 million, compared to $10.1 million for the first nine months of 2006. The gross profit for the first nine months was $3.8 million versus $3.6 million for the same period in 2006. The net loss for the period was $130 thousand, or $0.02 per share, versus a net profit of $557 thousand, or $0.07 per share for the same period last year.

Shareholders' equity on September 30, 2007 was $7.1 million, compared to $7.3 million on December 31, 2006. Current assets net of current liabilities at the end of the period were $1.2 million, compared to $2.6 million on December 31, 2006.

About Healthcare Technologies

Healthcare Technologies Ltd. through it subsidiaries and affiliate Gamidor Diagnostics (1984) Ltd. ,Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

Healthcare Technologies, Ltd.

Condensed Consolidated Statement of Operations

(U.S. Dollars in Thousands, Except Profit (Loss) Per Share Information)

Three Months Ended Nine Months Ended Year Ended

09/30/07 09/30/06 09/30/07 09/30/06 31/12/06

Sales $4,035 $3,066 $11,789 $10,116 $13,656

Gross profit $1,397 $1,025 $3,827 $3,591 $4,775

Net profit (Loss) $189 $34 $(130) $557 $210

Profit (Loss) per

share $0.02 $0.00 $(0.02) $0.07 $0.03

Weighted

average number

of Shares and

share equivalents

Outstanding

(in Thousands) 7,793 7,703 7,793 7,703 7,715

Consolidated Balance Sheet ,

(U.S $ in thousands)

09/30/07 09/30/06 12/31/06

Cash and cash

equivalents $238 $467 $361

Total current

assets $7,662 $7,055 $7,672

Total current

liabilities $6,442 $4,680 $5,055

Shareholder's

equity $7,151 $7,621 $7,315

Safe Harbor: This press release contains certain forward looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities Exchange Commission, specifically the most recent report on Form 20F that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: Healthcare Technologies Ltd

CONTACT: Eran Rotem CFO

+972-3-9277232/3


'/>"/>
SOURCE Healthcare Technologies Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
5. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
6. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Financial Highlights ... unaudited)Three Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$   ... Product Revenue 3539(10)%9498(4)%Kuvan Net Product ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
Breaking Biology News(10 mins):